Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
LNA-antimiR, miravirsen (SPC3649)
print preview
bookmark
share with colleague
General Information
Company
Santaris Pharma A/S
Description
Locked nucleic acid (LNA)-modified phosphorothioate anti-sense oligonucleotide targeting microRNA-122 (miR-122)
Molecular Target
MicroRNA-122 (miR-122)
Mechanism of Action
Antiviral agent
Latest Stage of Development
Phase II
Indication
Hepatitis C virus (HCV)
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy